Nillion: An unauthorized market maker sold NIL tokens, and the repurchase of the sold tokens has already begun.
BlockBeats News, November 20, Nillion stated in an article, "A certain market maker sold NIL tokens without the legal authorization of the Nillion Association, and refused to respond to any communication from the team during and for several hours after the flash sale.
We are taking immediate action. The Nillion Association has begun to use association funds to buy back the tokens that were sold. We also commit to using all funds obtained from the unauthorized sale by this market maker to repurchase more NIL tokens.
We are making every effort to pursue legal responsibility, coordinating with exchange partners to ensure that all accounts and wallets related to this incident have been frozen."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure
According to media reports citing sources familiar with the matter, SpaceX is preparing to complete a debt issuance totaling $40 billion, with an interest rate significantly higher than previous borrowing costs, reflecting growing investor concerns over financing for artificial intelligence (AI) infrastructure.
Tom Lee: The market is in a sell-off state, and tech stocks have reached support levels
TS Lombard scenario analysis: An AI bubble burst could trigger a 30% plunge in the S&P 500, wiping out 20 trillion dollars in market value—but don't rush to short!
Dario Perkins from TS Lombard predicted in a scenario analysis released on Thursday that if AI capital expenditure collapses, approximately $20 trillions in U.S. stock market value could evaporate, triggering credit losses of $125 billions to $190 billions.
Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline
Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.
Crypto prices
More
